Nemaura Pharma Limited Awarded the Prestigious 2016 Frost & Sullivan Award for Best Practices in Enabling Technology Leadership in Transdermal Drug Delivery

LOUGHBOROUGH, England–(BUSINESS WIRE)– Nemaura Pharma has been awarded the prestigious 2016 Frost & Sullivan
award for best practices in Enabling Technology Leadership in the
Transdermal Drug Delivery Industry.

The analysts stated that, “Nemaura Pharma’s drug delivery technology has
revolutionized the way drugs are delivered in the healthcare system.”
They spoke highly of Nemaura’s Memspatch liquid delivery system because
it is highly accurate, easy to use, and patient-friendly. The Memspatch
uses microneedle technology to insert several small needles no more than
few millimetres into the skin. The dose is dispersed over a larger
surface area than is possible with a single needle, facilitating faster
absorption. The judges pointed out that Nemaura has overcome the problem
of erratic dosing that has dogged traditional transdermal patches by
adding an applicator to the system—this allows for 100% needle
penetration.

“Conventional liquid vaccine has contamination and stability risks
associated with it,” said Frost & Sullivan Senior Research Analyst
Debarati Sengupta. “Nemaura Pharma has reformulated the liquid vaccine
into a stable, solid dose formulation, without any loss of potency.” The
Micro-Patch system works by inserting a super-sharp stainless steel
needle into the outer layer of the skin. The needle then retracts
completely, minimising the risk of stick injuries, and the solid dose
formulation remains deposited in the skin. The judges noted that the
system eliminates the need for cold-chain storage, which should lead to
significant savings and does not require a specialist to use it to
administer the drug.

“The solid and liquid microneedle-based drug delivery technologies
(Memspatch and Micro-Patch) provide pain-free, minimally-invasive drug
delivery with controlled drug dosage,” noted Debarati. “With superior
drug absorption, reduced or minimal drug stability or dosage issues,
this easy-to-use transdermal technology drives better patient compliance
and outcomes. With its strong overall performance, Nemaura Pharma has
earned Frost & Sullivan’s 2016 Enabling Technology Leadership Award.”

The award was made after an in-depth evaluation by Frost & Sullivan
analysts, including a review by a panel of industry experts. “We are
delighted and honoured to receive this accolade,” said Dr Faz Chowdhury,
CEO of Nemaura Pharma. “We have worked over several years to carefully
integrate human factors into what we envisage will become the world’s
leading injectable devices for a very wide range of drugs, and we
anticipate this will enable patients globally to benefit from less
intrusive and more intuitive devices for the routine administration of
vaccines and medicines.”

Notes for Editors.

About Nemaura Pharma Limited

A private specialist biotech company, Nemaura Pharma is strategically
positioned to work with global pharmaceutical companies, as well as new
biotechnology companies, to successfully bring both new and old drugs to
patients in superior delivery formulations and systems. Ultimately, we
aim to improve patient lifestyle and quality of life. Our advanced drug
delivery systems are designed to increase the effectiveness and safety
of therapeutic drugs, while also reducing complications due to patient
non-compliance, and mitigating the side effects of less efficient
delivery systems.

www.nemaura.co.uk

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration
with clients to leverage visionary innovation that addresses the global
challenges and related growth opportunities that will make or break
today’s market participants. For more than 50 years, we have been
developing growth strategies for the Global 1000, emerging businesses,
the public sector and the investment community.

http://ww2.frost.com/

Cautionary Statement Regarding Forward Looking Statements.

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current
expectations and are subject to risks and uncertainties that could cause
actual future results to differ materially from those expressed or
implied by such statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160815006206/en/